Hyperbaric Oxygen Therapy (HBOT): Evidence for Longevity & Healing

Quick answer: Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen at 1.5–3.0 atmospheres absolute (ATA), raising plasma oxygen concentration 10–15-fold above normal. A landmark 2020 clinical trial at Tel Aviv University demonstrated that 60 HBOT sessions produced a 20–38% increase in telomere length and a 37% reduction in senescent T cells — the first intervention in humans to reverse two key hallmarks of biological aging simultaneously.

What Is Hyperbaric Oxygen Therapy?

Hyperbaric oxygen therapy involves breathing 100% pure oxygen inside a pressurized chamber at atmospheric pressures greater than sea level (1 ATA). Standard clinical protocols range from 1.5 to 3.0 ATA depending on the indication. At these pressures, the lungs absorb far more oxygen than possible at normal pressure — oxygen dissolves directly into plasma rather than relying solely on hemoglobin transport.

At 2.0 ATA breathing 100% O2, arterial pO2 rises to approximately 1,400–1,500 mmHg (versus 90–100 mmHg breathing room air at sea level). This dramatic increase in dissolved oxygen allows oxygen delivery to ischemic or hypoxic tissue that red blood cells cannot reach due to compromised circulation, edema, or microvascular damage.

The U.S. Food and Drug Administration has approved HBOT for 13 specific indications, including diabetic foot ulcers, carbon monoxide poisoning, gas gangrene, decompression sickness, radiation tissue injury, and severe anemia. Beyond FDA-cleared indications, HBOT is being actively investigated for traumatic brain injury, long COVID, stroke recovery, and — most recently — longevity and biological age reversal.

The Physiology: How Hyperbaric Oxygen Works

HBOT operates through multiple overlapping mechanisms that extend well beyond simply delivering more oxygen to tissues.

Hyperoxic-Hypoxic Paradox and HIF-1α Activation

A counterintuitive mechanism drives much of HBOT’s regenerative effect. During HBOT sessions, tissue pO2 spikes dramatically. Between sessions, oxygen levels return to baseline — which, relative to the hyperoxic state just experienced, represents a relative hypoxia. This oscillation between hyperoxia and normoxia activates hypoxia-inducible factor 1-alpha (HIF-1α), the master transcription factor that drives angiogenesis, stem cell mobilization, and metabolic adaptation to oxygen fluctuation.

HIF-1α activation triggers downstream expression of vascular endothelial growth factor (VEGF), erythropoietin (EPO), and stromal cell-derived factor-1 (SDF-1) — collectively driving new blood vessel formation, red blood cell production, and bone marrow stem cell recruitment to ischemic tissue. This is why repeated HBOT sessions (not single exposures) produce lasting regenerative effects even after the treatment course ends.

Stem Cell Mobilization

A controlled clinical study by Thom and colleagues demonstrated that 20 HBOT sessions at 2.0 ATA produced an 800% increase in circulating CD34+ stem cells — endothelial progenitor cells responsible for vascular repair and tissue regeneration (Thom 2006, American Journal of Physiology). This mobilization persists for approximately 20 days post-treatment. The magnitude of stem cell mobilization from HBOT exceeds that achieved by pharmacological agents including G-CSF (granulocyte colony-stimulating factor) in some protocols.

Mitochondrial Biogenesis and ATP Production

Hyperoxic conditions during HBOT increase mitochondrial membrane potential and upregulate PGC-1α — the same transcription factor activated by Zone 2 exercise and cold therapy — driving mitochondrial biogenesis. Elevated oxygen availability increases electron transport chain efficiency, with measurable increases in ATP production. Simultaneously, HBOT induces controlled reactive oxygen species (ROS) signaling at low levels (hormetic ROS), activating Nrf2 and upregulating endogenous antioxidant defenses including superoxide dismutase (SOD), catalase, and glutathione peroxidase.

Anti-Inflammatory Signaling

HBOT suppresses NF-κB activity and downstream pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α). It reduces neutrophil-endothelial adhesion, limiting ischemia-reperfusion injury. In traumatic brain injury models, HBOT reduces microglial activation and neuroinflammatory cascades within 24–72 hours of treatment initiation. These anti-inflammatory effects are particularly relevant for conditions driven by chronic low-grade inflammation — metabolic syndrome, autoimmune conditions, and neurodegeneration.

HBOT and Longevity: The Tel Aviv Aging Trial

The most scientifically significant recent HBOT research comes from the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, Tel Aviv University. In 2020, Dr. Shai Efrati’s team published a landmark randomized controlled trial in the journal Aging (Hachmo et al., 2020) that demonstrated something previously considered impossible: HBOT reversed two cellular hallmarks of biological aging in healthy older adults.

The protocol: 60 sessions of HBOT at 2.0 ATA, 90 minutes per session, 5 sessions per week, over 12 weeks, with 5-minute air breaks every 20 minutes to amplify the hyperoxic-hypoxic cycling effect. Participants were healthy adults aged 64 and older with no significant medical conditions.

Results were extraordinary:

Telomere lengthening: Telomere length increased by an average of 20–38% depending on cell type analyzed — the largest documented telomere extension from any intervention in human clinical trial history. For context, telomeres typically shorten 1–3% per year of normal aging. These participants effectively reversed approximately 20 years of telomeric aging in 12 weeks.

Senescent cell clearance: The percentage of senescent T cells (CD28-/CD57+ and CD28-/PD-1+) decreased by 37% for T-helper cells and 11% for cytotoxic T cells. Reducing the senescent cell burden reduces SASP (senescence-associated secretory phenotype) secretion — the same goal targeted by pharmaceutical senolytics like dasatinib and quercetin. HBOT represents a non-pharmacological approach achieving parallel senolytic outcomes through immune-mediated mechanisms (NK cell activation, enhanced immune surveillance).

A companion study from the same group (Hadanny et al., 2020, Aging) demonstrated that the same 60-session protocol produced significant improvements in cognitive function — attention, information processing speed, and executive function — in healthy older adults. These improvements correlated with increased cerebral blood flow measured by perfusion MRI.

Wound Healing and Diabetic Foot Ulcers

HBOT has the strongest and most replicated evidence base in wound healing, particularly for diabetic foot ulcers — one of the FDA’s approved indications. Diabetic foot ulcers affect 15–25% of people with diabetes over their lifetime and are the leading cause of non-traumatic lower limb amputation worldwide.

The 2015 Cochrane systematic review of HBOT for diabetic foot ulcers (Kranke et al., 2015) analyzed 10 randomized trials involving 531 patients. HBOT significantly reduced the risk of major amputation at one year compared with control treatment (relative risk 0.29, 95% CI 0.13–0.66). A large observational study using Medicare data found that HBOT was associated with a 30% reduction in amputation rates among Medicare beneficiaries with diabetic foot ulcers who received the treatment.

The mechanism is straightforward: diabetic foot ulcers fail to heal primarily due to tissue hypoxia from peripheral vascular disease and microvascular damage. Wound healing requires oxygen for collagen synthesis, fibroblast proliferation, angiogenesis, and bactericidal activity of neutrophils (oxidative burst). HBOT directly addresses this oxygen deficit, raising wound tissue pO2 from below 10 mmHg (insufficient for healing) to above 30 mmHg (permissive for repair) for hours after each session.

Traumatic Brain Injury and PTSD

Military TBI and PTSD have driven significant HBOT research over the past two decades. The rationale: even mild TBI produces diffuse axonal injury, microhemorrhages, and regions of chronic cerebral hypoperfusion that persist years after injury. Conventional treatment does not address the underlying hypoperfusion.

The most rigorous military HBOT trial was published in PLOS ONE by Efrati and colleagues (2013), who randomized 56 patients with post-concussion syndrome and PTSD who had failed conventional treatment to HBOT (40 sessions, 1.5 ATA) versus a sham crossover control. HBOT-treated patients showed significant improvements in post-concussion symptoms, PTSD symptom scores, cognitive performance (attention, memory, executive function, and information processing speed), and quality of life metrics. Brain SPECT imaging documented increased perfusion in hypoperfused regions correlating with clinical improvement.

A 2022 randomized controlled trial by Boussi-Gross et al. published in PLOS ONE demonstrated that HBOT (60 sessions, 2.0 ATA) significantly improved post-COVID cognitive symptoms — brain fog, memory, attention — with corresponding improvements in brain perfusion on MRI, even 6–12 months after acute COVID illness. This study contributed to growing interest in HBOT as a treatment for long COVID.

Important note: A 2022 Cochrane review of HBOT for TBI found that while multiple RCTs show benefit, study quality varies and independent replication is needed for definitive clinical recommendations. The evidence is promising but not yet conclusive for routine TBI treatment outside specialized centers.

Long COVID and Post-Viral Syndrome

Long COVID — characterized by fatigue, brain fog, dyspnea, dysautonomia, and cognitive impairment persisting beyond 12 weeks post-infection — shares pathophysiology with conditions HBOT has historically treated: microthrombi, endothelial dysfunction, mitochondrial dysfunction, chronic neuroinflammation, and microglial activation.

Zilberman-Itskovich et al. (2022, Scientific Reports) published the first double-blind, sham-controlled trial of HBOT for long COVID. In 73 patients with post-COVID syndrome, 40 sessions of HBOT (2.0 ATA, 90 minutes) produced significant improvements in cognitive function (attention, memory, executive function, processing speed), fatigue scores, sleep quality, anxiety, and pain — all primary outcome measures. Resting-state fMRI showed increased functional connectivity in frontal and parietal networks correlating with cognitive improvement.

A subsequent trial by the same group (Hadanny et al., 2024) enrolled 154 long COVID patients and replicated these findings, with improvements in cardiopulmonary exercise testing and VO2max alongside cognitive and symptom measures. HBOT is now offered at multiple long COVID centers internationally, though it remains off-label for this indication in the United States.

Stroke Recovery and Neuroplasticity

Post-stroke disability remains undertreated, particularly chronic neurological deficits that persist years after the acute event. The conventional assumption is that stroke recovery plateaus at 6–12 months. HBOT challenges this assumption by targeting the ischemic penumbra — metabolically compromised but electrically silent neurons surrounding the infarct that remain potentially salvageable for years post-stroke.

Efrati et al. (2013, PLOS ONE) randomized 74 stroke patients with chronic neurological deficits (averaging 4 years post-stroke) to HBOT (40 sessions, 2.0 ATA) versus a crossover control. HBOT produced statistically significant improvements in neurological function, quality of life, and activities of daily living. Brain SPECT imaging confirmed increased perfusion in the ischemic penumbra regions. The finding that neurons dysfunctional for 4+ years post-stroke could recover function challenged the established model of permanent stroke deficit.

Radiation Tissue Injury

Osteoradionecrosis (radiation-induced bone death, typically of the jaw following head and neck radiation) and radiation cystitis are two of the most debilitating late effects of cancer treatment. Both result from radiation-induced hypovascularization and tissue hypoxia — exactly the pathophysiology HBOT addresses most directly.

HBOT for osteoradionecrosis of the jaw has the strongest evidence base among radiation injury indications, with multiple retrospective series and prospective trials documenting healing rates of 60–80% in cases resistant to conventional treatment. The standard protocol (Marx protocol) consists of 20 pre-operative sessions at 2.4 ATA followed by 10 post-operative sessions, combined with surgical debridement. This indication is FDA-approved and routinely covered by insurance.

For radiation proctitis and cystitis, systematic reviews support HBOT with resolution rates of 60–75% for radiation proctitis bleeding and significant symptom improvement in radiation cystitis, with minimal adverse effects.

HBOT Protocols: Hard Chamber vs. Mild Hyperbaric

A critical distinction exists between FDA-cleared hard chamber HBOT and “mild hyperbaric” or “soft chamber” therapy marketed in wellness settings.

Hard chamber HBOT: Rigid steel or acrylic chamber capable of achieving 2.0–3.0 ATA. Patients breathe 100% medical-grade oxygen via mask or hood. Required for all FDA-approved medical indications. Typically hospital-based or freestanding wound care centers. Cost: $250–$450 per session without insurance.

Mild hyperbaric therapy (mHBT): Portable inflatable chambers operating at 1.3–1.5 ATA, breathing ambient air or 40% oxygen via mask. These pressures are insufficient to achieve the plasma oxygen levels demonstrated in clinical trials. At 1.3 ATA breathing air, the increase in dissolved plasma oxygen is modest — approximately 30% above atmospheric — compared with 1,000%+ at 2.0 ATA breathing 100% O2. The clinical evidence base for mHBT is substantially weaker than for hard chamber HBOT, and the Hachmo aging trial and all cited medical indications used hard chamber protocols.

For longevity and neurological applications, the published evidence uniformly uses hard chamber protocols at ≥2.0 ATA with 100% oxygen. Wellness facilities offering 1.3 ATA air chambers are providing a fundamentally different intervention — one with a separate and much more limited evidence base.

Standard Clinical Protocols

Dosing parameters in HBOT are defined by three variables: pressure (ATA), oxygen concentration (%), and duration (minutes). The most commonly used longevity/neurological protocol follows the Aviv Science protocol derived from the Hachmo 2020 trial:

Longevity/cognitive protocol: 60 sessions at 2.0 ATA, 90 minutes per session, with three 5-minute breaks breathing ambient air at equal intervals (effectively delivering six 20-minute hyperoxic cycles per session). Sessions 5 days per week for 12 weeks. The air breaks are intentional — they create the hyperoxic-hypoxic cycling that maximizes HIF-1α and VEGF activation.

Wound healing protocol: 20–40 sessions at 2.0–2.4 ATA, 90–120 minutes, 5–7 days per week until wound healing endpoint is reached or maximum response determined.

TBI/post-concussion protocol: 40 sessions at 1.5 ATA (some centers use 2.0 ATA), 60 minutes, 5 days per week for 8 weeks.

Radiation injury protocol: 30 sessions pre-operatively + 10 post-operatively at 2.4 ATA, 90 minutes, for osteoradionecrosis (Marx protocol).

Safety Profile and Contraindications

HBOT has an excellent safety profile at therapeutic pressures. Over 4 million HBOT sessions are administered annually in the United States with serious adverse events occurring at rates below 0.1%.

Common side effects (5–20% of patients): Middle ear barotrauma (discomfort or pain during pressurization, occasionally tympanic membrane rupture), sinus squeeze (frontal or maxillary pain during descent), and temporary myopia (reversible refractive changes after 20+ sessions, resolving within 4–6 weeks post-treatment).

Serious but rare adverse events (<0.1%): Central nervous system oxygen toxicity (grand mal seizure) occurring at pressures above 3.0 ATA or with prolonged exposure; pulmonary oxygen toxicity with excessive cumulative oxygen dose; arterial gas embolism (theoretical risk with barotrauma).

Absolute contraindications: Untreated tension pneumothorax (air in chest cavity). HBOT should not be initiated until pneumothorax is fully treated due to risk of gas expansion during decompression.

Relative contraindications requiring physician evaluation: Concurrent treatment with doxorubicin (anthracycline chemotherapy — increased cardiotoxicity risk), bleomycin (pulmonary toxicity amplification), disulfiram, or cis-platinum. Upper respiratory infection (impairs pressure equalization). History of thoracic surgery. Uncontrolled seizure disorder. Claustrophobia. Congenital spherocytosis. High fever.

All HBOT should be prescribed and supervised by a physician trained in hyperbaric medicine. The Undersea and Hyperbaric Medical Society (UHMS) certifies hyperbaric physicians and facilities maintaining safety standards for clinical HBOT.

HBOT and the Functional Medicine Framework

Within a functional medicine approach, HBOT is most relevant as an adjunct intervention for conditions driven by mitochondrial dysfunction, chronic inflammation, tissue hypoxia, or accelerated biological aging. It fits naturally into longevity protocols alongside:

Senolytics and senostatics: HBOT achieves senescent cell reduction (37% in T cells per Hachmo 2020) through immune-mediated mechanisms — enhanced NK cell activity and immune surveillance — while senolytics like dasatinib + quercetin and fisetin achieve it through direct BCL-2/BCL-XL inhibition. These mechanisms are complementary, not redundant. A combined protocol targeting senescent cells through multiple pathways simultaneously is mechanistically rational, though no clinical trial has yet combined pharmacological senolytics with HBOT.

Zone 2 training: Zone 2 exercise and HBOT both activate PGC-1α and drive mitochondrial biogenesis through different upstream signals (AMPK/SIRT1 vs. hyperoxic ROS/HIF-1α cycling). VEGF and angiogenesis are upregulated by both, creating additive capillary density increases in tissue.

NAD+ precursors: NAD+ supports mitochondrial function and SIRT1 activation. HBOT increases mitochondrial electron transport efficiency and ATP production. Both interventions converge on mitochondrial optimization from complementary angles.

Red light therapy (photobiomodulation): PBM and HBOT share the cytochrome c oxidase (CcO) as an upstream target — PBM activates CcO via photon absorption, HBOT increases CcO substrate availability. Both drive ATP production and Nrf2 antioxidant activation. Transcranial PBM and HBOT have been used in combination protocols for TBI with additive neurological benefit in case series.

Insurance Coverage and Access

Medicare and most private insurers cover HBOT for the 13 FDA-approved indications. Coverage requires prior authorization in most cases, documentation of qualifying diagnosis, and treatment at a Medicare-certified hyperbaric facility. Wound care-related HBOT (diabetic foot ulcers, radiation injury) typically has the most straightforward coverage pathways.

Off-label indications — TBI, post-stroke, long COVID, neurological conditions, and longevity protocols — are not covered by insurance and are paid out-of-pocket. Full longevity protocols (60 sessions) at established centers run $15,000–$25,000 total. Aviv Clinics (Florida and Dallas) charges approximately $22,000 for the full 60-session cognitive/longevity protocol with full biomarker workup pre and post.

For patients with chronic conditions on the borderline of covered indications, consultation with a UHMS-certified hyperbaric physician can determine whether an FDA-approved indication applies, potentially enabling insurance coverage for a portion of treatment costs.

Evaluating HBOT Providers

Quality and safety in HBOT vary substantially across providers. Key questions when evaluating a hyperbaric center:

UHMS accreditation: The Undersea and Hyperbaric Medical Society Accredited Program designation ensures facility meets safety standards for equipment, staffing, physician training, and emergency protocols. Accredited facilities maintain oxygen fire safety protocols, emergency abort procedures, and trained attendants present during all sessions.

Physician involvement: All clinical HBOT should be prescribed by a physician, with dive physician oversight. Wellness centers operating soft chambers at 1.3 ATA without physician supervision are not delivering clinical HBOT.

Chamber type and pressure capability: Confirm the facility operates monoplace or multiplace chambers capable of 2.0 ATA minimum for neurological and longevity indications. Soft inflatable chambers max at 1.3–1.5 ATA and are insufficient for evidence-based protocols.

Oxygen purity: Medical-grade 100% oxygen, not ambient air, is required for therapeutic effect. Ask what oxygen delivery system is used.

FAQs About Hyperbaric Oxygen Therapy

How many HBOT sessions does it take to see results?
The timeline depends on the indication. For wound healing, measurable improvement typically occurs within 10–20 sessions. For neurological indications (TBI, stroke, post-COVID brain fog), most patients report initial improvement after 20–30 sessions, with maximum benefit at 40–60 sessions. For the longevity telomere-lengthening protocol, the published outcome data is from the complete 60-session course — telomere changes were measured post-completion. For acute indications like carbon monoxide poisoning or decompression sickness, even 1–3 sessions can be life-saving.

Is HBOT safe to do if you have cancer?
This is nuanced. HBOT is not contraindicated in most cancer diagnoses and is FDA-approved for radiation tissue injuries caused by cancer treatment. Concerns historically raised about HBOT theoretically promoting tumor growth via VEGF and angiogenesis have not been supported by clinical evidence — in fact, HBOT may enhance chemotherapy and radiation effectiveness in hypoxic tumors by increasing tumor oxygenation. However, HBOT should not be used concurrently with certain chemotherapy agents (doxorubicin, bleomycin, cisplatin) due to potentiation of drug toxicity. All cancer patients considering HBOT should consult both their oncologist and a hyperbaric physician before initiating treatment.

Does HBOT help with anti-aging at home with a portable chamber?
Home soft chambers at 1.3 ATA breathing ambient air or 40% oxygen deliver a fraction of the physiological stimulus of clinical HBOT at 2.0 ATA with 100% oxygen. The published longevity research (telomere lengthening, senescent cell reduction) used hard chamber protocols at 2.0 ATA with 100% oxygen — a protocol requiring a clinical facility. Home chambers may provide mild benefits via modest oxygen enhancement and pressure effects, but should not be expected to replicate the outcomes from published clinical trials. They are not equivalent to clinical HBOT.

What does HBOT feel like?
The experience varies by chamber type. In a monoplace chamber (single-person acrylic tube), patients lie comfortably and breathe ambient chamber air (which is 100% O2 at therapeutic pressure). In a multiplace chamber, patients sit or lie and breathe through a mask or hood while the chamber pressurizes with air. The primary sensation is ear pressure during pressurization, similar to descending in an airplane — relieved by swallowing, yawning, or the Valsalva maneuver. Once at pressure, most patients read, watch videos, or sleep comfortably. Sessions last 60–90 minutes. Some patients experience mild fatigue after initial sessions; most report increased energy and improved sleep quality within 2–3 weeks of regular treatment.

If you are exploring hyperbaric oxygen therapy as part of a functional medicine or longevity protocol, comprehensive evaluation of your current biological age markers, mitochondrial function, inflammatory burden, and relevant biomarkers should precede and follow any HBOT course to objectively measure response. Our office provides the integrative functional medicine evaluation necessary to determine whether HBOT is appropriate for your specific case and to track objective outcomes throughout treatment. Contact us at (810) 206-1402 to schedule a consultation.

Hyperbaric Oxygen Therapy (HBOT): Evidence, Longevity Research, and Clinical Protocols